Hence, one might seek to enhance tumor suppressor CDC73’s stability in cancer cells by maintaining its phosphorylated state, thus inhibiting its ubiquitination and degradation mediated by UBR5, as a potential therapeutic strategy for breast cancer patients with low CDC73 levels. The gene discussed is UBR5; the disease is breast carcinoma.